In this study, we aim to evaluate the role of maintenance capecitabine by comparing 2 arms of metastatic cancer pancreas patients in the first line , the first arm will receive 4 months of induction FOLFRINOX the maintenance capecitabine and the second arm will receive 4 months of FOLFRINOX then kept under follow-up:~•Primary end point: PFS.~•Secondary end points: OS, QOL and Toxicity.
A randomized phase II study evaluating maintenance therapy after first line induction chemotherapy in metastatic cancer pancreas.